G J Nabel

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Rational design of vaccines for AIDS and influenza
    Gary J Nabel
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Trans Am Clin Climatol Assoc 123:9-15; discussion 15-6. 2012
  2. ncbi Characterization of human adenovirus 35 and derivation of complex vectors
    Duncan McVey
    Department of Research, GenVec, Inc, Gaithersburg, MD 20874, USA
    Virol J 7:276. 2010
  3. ncbi Vaccine for AIDS and Ebola virus infection
    Gary J Nabel
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    Virus Res 92:213-7. 2003
  4. ncbi Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine
    Gary J Nabel
    National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 16:1389-91. 2010
  5. ncbi Genetic, cellular and immune approaches to disease therapy: past and future
    Gary J Nabel
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nat Med 10:135-41. 2004
  6. ncbi Immunology. Close to the edge: neutralizing the HIV-1 envelope
    Gary J Nabel
    Vaccine Research Center (VRC, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 308:1878-9. 2005
  7. ncbi HIV vaccine strategies
    Gary J Nabel
    Vaccine Research Center, NIAID, National Institute of Health, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    Vaccine 20:1945-7. 2002
  8. ncbi Challenges and opportunities for development of an AIDS vaccine
    G J Nabel
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3005, USA
    Nature 410:1002-7. 2001
  9. ncbi Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3017, USA
    J Infect Dis 194:1638-49. 2006
  10. ncbi Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses
    Marc Tritel
    Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    J Immunol 171:2538-47. 2003

Detail Information

Publications95

  1. ncbi Rational design of vaccines for AIDS and influenza
    Gary J Nabel
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Trans Am Clin Climatol Assoc 123:9-15; discussion 15-6. 2012
    ..Similarly, for influenza, understanding of this target has led to structural and genetic approaches to the development of new immunogens that provide a proof of concept for universal influenza vaccination...
  2. ncbi Characterization of human adenovirus 35 and derivation of complex vectors
    Duncan McVey
    Department of Research, GenVec, Inc, Gaithersburg, MD 20874, USA
    Virol J 7:276. 2010
    ..The structure of the viral genome and life cycle of Ad35 differs from the better characterized Ad5 and these differences require differences in the strategies for the generation of vectors for gene delivery...
  3. ncbi Vaccine for AIDS and Ebola virus infection
    Gary J Nabel
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    Virus Res 92:213-7. 2003
    ..Further evaluation in humans will allow an assessment of their potential efficacy and point the way to the development of more successful vaccines...
  4. ncbi Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine
    Gary J Nabel
    National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 16:1389-91. 2010
    ..Newer vaccine approaches have succeeded in eliciting broadly neutralizing antibodies to highly conserved yet vulnerable regions of the hemagglutinin and suggest potential pathways for the development of universal influenza vaccines...
  5. ncbi Genetic, cellular and immune approaches to disease therapy: past and future
    Gary J Nabel
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nat Med 10:135-41. 2004
    ..Innovations in gene delivery have not only catalyzed the nascent field of human gene therapy, but may also ultimately impact human health by advancing recombinant vaccine technology...
  6. ncbi Immunology. Close to the edge: neutralizing the HIV-1 envelope
    Gary J Nabel
    Vaccine Research Center (VRC, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 308:1878-9. 2005
  7. ncbi HIV vaccine strategies
    Gary J Nabel
    Vaccine Research Center, NIAID, National Institute of Health, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    Vaccine 20:1945-7. 2002
    ....
  8. ncbi Challenges and opportunities for development of an AIDS vaccine
    G J Nabel
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3005, USA
    Nature 410:1002-7. 2001
    ....
  9. ncbi Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3017, USA
    J Infect Dis 194:1638-49. 2006
    ..This multiclade rAd5 HIV-1 vaccine is now being evaluated in combination with a multiclade HIV-1 DNA plasmid vaccine...
  10. ncbi Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses
    Marc Tritel
    Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    J Immunol 171:2538-47. 2003
    ..Together, these data suggest a new immunization approach for elicitation of long term humoral and cellular immune responses...
  11. ncbi Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Bethesda, MD 20892 3017, USA
    Vaccine 25:4085-92. 2007
    ..Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation...
  12. ncbi Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    ..Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design...
  13. ncbi Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41
    Franck Lemiale
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892, United States
    Vaccine 25:2074-84. 2007
    ..Ad41-based constructs are attractive vaccine vectors alone or in combination with Ad5 adenovectors, since each vector type can provide circumvention of pre-existing immunity to the other...
  14. ncbi Vaccines for the prevention of HIV-1 disease
    J R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    Curr Opin Immunol 13:489-95. 2001
    ....
  15. ncbi Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine
    Wataru Akahata
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland 20892-3005, USA
    J Virol 79:626-31. 2005
    ..These data suggest that DNA vaccines encoding separated HIV polypeptides generate immune responses similar to those generated by viral particles...
  16. ncbi Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys
    Norman L Letvin
    Vaccine Research Center, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    J Virol 78:7490-7. 2004
    ....
  17. ncbi Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
    Richard A Koup
    Vaccine Research Center, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9015. 2010
    ..Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies...
  18. ncbi Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Bethesda, MD 20852, USA
    Vaccine 23:5404-10. 2005
    ..Thus, gene-based vaccination with NP may contribute to protective immunity against diverse influenza viruses through its ability to stimulate cellular immunity...
  19. ncbi Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model
    Srinivas S Rao
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 24:367-73. 2006
    ....
  20. ncbi Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens
    Lan Wu
    Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Bldg. 40, MSC-3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA
    J Virol 79:8024-31. 2005
    ..These findings suggest that the diversity of the CD4 immune response is increased by DNA/ADV prime-boost vaccination and that these components work synergistically to enhance T-cell epitope recognition...
  21. ncbi A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, MSC 2610, Bethesda, MD 20892 3017, USA
    Vaccine 26:6338-43. 2008
    ..Over 8000 cases and 900 deaths occurred during the epidemic. We report the safety and immunogenicity of a SARS DNA vaccine in a Phase I human study...
  22. ncbi Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892-3005, USA
    Nature 424:681-4. 2003
    ..This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses...
  23. ncbi Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope
    Lan Wu
    Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Bldg. 40, MSC-3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA
    Vaccine 24:4995-5002. 2006
    ....
  24. ncbi Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization
    Wing Pui Kong
    Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    J Virol 79:13915-23. 2005
    ..Because both cellular and humoral immune responses are generated by gene-based vaccination and inactivated viral boosting, this strategy may prove useful in the generation of SARS-CoV vaccines...
  25. ncbi Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Med 3:e177. 2006
    ..GP can exert cytopathic effects on transfected cells in vitro, and multiple GP forms have been identified in nature, raising the question of which would be optimal for a human vaccine...
  26. ncbi Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
    Bimal K Chakrabarti
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA
    Vaccine 23:3434-45. 2005
    ..These studies suggest that combinations of Env immunogens, despite the limited reactivity of the V3 from each component, can be used to expand the breadth of the neutralizing antibody response...
  27. ncbi Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors
    Sung Youl Ko
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    J Virol 83:748-56. 2009
    ....
  28. ncbi Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization
    Cheng Cheng
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892 3005, USA
    J Virol 84:630-8. 2010
    ..These results have implications for future AIDS vaccine trials and the design of next-generation gene-based vaccine vectors...
  29. ncbi Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice
    Anne C Moore
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-3005, USA
    J Virol 76:243-50. 2002
    ....
  30. ncbi Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects
    Jorge A Tavel
    Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 44:601-5. 2007
    ..To evaluate the safety and immunogenicity of a candidate HIV DNA vaccine administered using a needle-free device...
  31. ncbi Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs
    Yuuei Shu
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Vaccine 25:1398-408. 2007
    ....
  32. ncbi Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system
    Franck Lemiale
    Vaccine Research Center, NIAID/National Institutes of Health, MSC 3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA
    J Virol 77:10078-87. 2003
    ....
  33. ncbi A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
    Zhi-Yong Yang
    Vaccine Research Center, NIAID, National Institutes of Health, Building 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005, USA
    Nature 428:561-4. 2004
    ..Gene-based vaccination for the SARS-CoV elicits effective immune responses that generate protective immunity in an animal model...
  34. ncbi Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization
    Bimal K Chakrabarti
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-3005, USA
    J Virol 76:5357-68. 2002
    ..Importantly, this modified Env, gp140 Delta CFI, stimulated the antibody response to native gp160 while it retained its ability to induce a CTL response, a desirable feature for an AIDS vaccine...
  35. ncbi Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression
    Y Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 75:4947-51. 2001
    ..A Gag-Pol fusion protein stimulated cytotoxic T lymphocyte and antibody responses to Gag and Pol, while a Gag-Pol pseudoparticle did not elicit substantial Pol responses. This fusion protein may be useful for AIDS vaccines...
  36. ncbi Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region
    Gilad Ofek
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 84:2955-62. 2010
    ..Together, the results provide a more complete understanding of the 2F5 mechanism of HIV-1 neutralization and indicate ways to enhance the potency of MPER-directed antibodies...
  37. ncbi The rational design of an AIDS vaccine
    Daniel C Douek
    Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Building 40, MSC-3005, 40 Convent Drive, Bethesda, MD 20892, USA
    Cell 124:677-81. 2006
    ..AIDS vaccine design requires a scientifically driven, rational approach that encompasses the latest advances in viral molecular genetics, structural biology, and immunology...
  38. ncbi Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity
    Lingshu Wang
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892 3005, USA
    J Virol 83:7166-75. 2009
    ..These studies suggest that induction of primary immune responses by rAd5 gut immunization and subsequent systemic boosting elicits potent antigen-specific gut mucosal responses...
  39. ncbi Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010
    ..Partial receptor mimicry and extensive affinity maturation thus facilitate neutralization of HIV-1 by natural human antibodies...
  40. ncbi Overcoming immunity to a viral vaccine by DNA priming before vector boosting
    Zhi-Yong Yang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-3005, USA
    J Virol 77:799-803. 2003
    ..In summary, it is possible to counteract prior viral immunity by priming with a nonviral, DNA vaccine...
  41. ncbi Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines
    Wing-pui Kong
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-3005, USA
    J Virol 77:12764-72. 2003
    ..Such combinations of immunogens may help to address concerns about viral genetic diversity for a prospective HIV-1 vaccine...
  42. ncbi Induction of broadly neutralizing H1N1 influenza antibodies by vaccination
    Chih Jen Wei
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD 20892 3005, USA
    Science 329:1060-4. 2010
    ..Cross-neutralization of H1N1 subtypes elicited by this approach provides a basis for the development of a universal influenza vaccine for humans...
  43. ncbi Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys
    Norman L Letvin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 312:1530-3. 2006
    ..These immune correlates of vaccine efficacy should guide the evaluation of AIDS vaccines in humans...
  44. ncbi A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes, Bethesda, MD 20892 3017, USA
    Clin Vaccine Immunol 13:1267-77. 2006
    ....
  45. ncbi A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial
    Julie E Martin
    Vaccine Research Center, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    J Infect Dis 196:1732-40. 2007
    ..West Nile virus (WNV) is a mosquito-borne flavivirus that can cause severe meningitis and encephalitis in infected individuals. We report the safety and immunogenicity of a WNV DNA vaccine in its first phase 1 human study...
  46. ncbi Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1650-60. 2006
    ..Vaccine Research Center (VRC) 004 is the first phase 1 dose-escalation study of a multiclade HIV-1 DNA vaccine...
  47. ncbi Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins
    John R Mascola
    Vaccine Research Center, NIAID, NIH, 40 Convent Dr, Bethesda, MD 20892, USA
    J Virol 79:771-9. 2005
    ....
  48. ncbi Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
    Zhongyu Zhu
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, SAIC Frederick, Inc, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 104:12123-8. 2007
    ..These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections...
  49. ncbi Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity
    Zhi Yong Yang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health, Building 40, Room 4502, Mailstop Code MSC 3005, 40 Convent Drive, Bethesda, MD 20892, USA
    Science 317:825-8. 2007
    ..Structure-based modification of HA specificity can guide the development of preemptive vaccines and therapeutic monoclonal antibodies that can be evaluated before the emergence of human-adapted H5N1 strains...
  50. ncbi Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA Midwest Research Institute, Frederick, MD 21702, USA
    Virology 381:106-15. 2008
    ....
  51. ncbi Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule
    Nancy J Sullivan
    Biodefense Research Section, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 7:393-400. 2009
    ..This research provides a basis for bridging the gap from basic research to human vaccine responses in support of the licensing of vaccines through the animal rule...
  52. ncbi Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts
    Rebecca L Sheets
    U S Public Health Service, Vaccine Production Program, NIH NIAID Vaccine Research Center, Bethesda, Maryland 20892 7628, USA
    Toxicol Sci 91:610-9. 2006
    ..2006) to demonstrate the safety and suitability for investigational human use of DNA plasmid vaccine candidates for a variety of infectious disease prevention indications...
  53. ncbi Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain
    Lan Wu
    Vaccine Research Center, NIAID, National Institutes of Health, Bldg 40, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    J Virol 83:5077-86. 2009
    ..Structurally designed membrane-anchored ODs represent candidate immunogens to elicit or to allow the detection of broadly neutralizing antibodies to the conserved site of CD4 binding on HIV-1 gp120...
  54. ncbi Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Vaccine Immunol 19:1792-7. 2012
    ..m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens...
  55. ncbi A gene-based avian influenza vaccine in poultry
    S S Rao
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    Poult Sci 88:860-6. 2009
    ..Here we review the features of gene-based vaccination that may facilitate the control of HPAI H5N1 in poultry, and highlight the development of a hemagglutinin-based multivalent DNA vaccine that confers protection in mice and chickens...
  56. ncbi The Gordon Wilson Lecture: viruses and human disease
    G J Nabel
    Vaccine Research Center, National Institutes of Health, 40 Convent Drive, MSC 3005, Bethesda, MD 20892, USA
    Trans Am Clin Climatol Assoc 112:79-84; discussion 86-8. 2001
    ..In this way, Ebola virus infection provides a useful paradigm for understanding the genetic determinants of viral disease and in facilitating the development of treatments and prevention of viral infections...
  57. ncbi Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination
    Wing Pui Kong
    Vaccine Research Center, NIAID, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    J Virol 83:2201-15. 2009
    ..Synthetic mosaic HIV-1 antigens can therefore induce T-cell responses with expanded breadth and may facilitate the development of effective T-cell-based HIV-1 vaccines...
  58. ncbi Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses
    Xueling Wu
    Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA
    Virology 380:285-95. 2008
    ..These findings confirm that V3 antibodies recognize most primary viral strains, but that the epitope often has limited accessibility in the context of native envelope spike...
  59. ncbi A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection
    Wataru Akahata
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 16:334-8. 2010
    ..Immunization with alphavirus VLP vaccines represents a strategy to contain the spread of CHIKV and related pathogenic viruses in humans...
  60. ncbi Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120
    Lei Chen
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 326:1123-7. 2009
    ..This incompatibility, the consequence of slight differences in CD4BS recognition, renders HIV-1 resistant to all but the most accurately targeted antibodies...
  61. ncbi Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus
    Chih Jen Wei
    Vaccine Research Center, NIAID, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    J Virol 82:6200-8. 2008
    ..Taken together, these results suggest that recombinant HA proteins as individual or oligomeric trimers can elicit potent neutralizing antibody responses to avian H5N1 influenza viruses...
  62. ncbi Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells
    Cheng Cheng
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 3:e25. 2007
    ..Understanding of these interactions facilitates the development of vectors that target DCs through alternative receptors that can improve safety while retaining the immunogenicity of rAd vaccines...
  63. ncbi Structural definition of a conserved neutralization epitope on HIV-1 gp120
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 445:732-7. 2007
    ..A site of vulnerability, related to a functional requirement for efficient association with CD4, can therefore be targeted by antibody to neutralize HIV-1...
  64. ncbi Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo
    L M Akyurek
    Vascular Biology Branch, NHLBI National Institutes of Health, Bethesda, MD 20892, USA
    Mol Ther 3:779-86. 2001
    ..These modifications in TKciteGK vectors and GCV showed enhanced efficacy at lower prodrug doses, leading to improved safety for cardiovascular gene therapy...
  65. ncbi Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity
    Mitsuo Honda
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 183:2425-34. 2009
    ..These findings suggest that different gene-based vectors generate peptides with alternative conformations within MHC-I that elicit distinct T cell responses after vaccination...
  66. ncbi Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1
    Peter D Kwong
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892, USA
    Cell Host Microbe 6:292-4. 2009
    ....
  67. ncbi Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity
    Chantelle L Hood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 4502, Building 40, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    J Virol 84:2972-82. 2010
    ..Together, these data suggest that CatL cleavage of EBOV GP exposes its receptor-binding domain, thereby facilitating access to a putative cellular receptor in steps that lead to membrane fusion...
  68. ncbi Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis
    Lakshmanan Ganesh
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 40, Room 4502, 40 Convent Dr, Bethesda, Maryland 20892 3005, USA
    Mol Cell Biol 26:3864-74. 2006
    ..Taken together, these data suggest that PRMT2 inhibits cell activation and promotes programmed cell death through this NF-kappaB-dependent mechanism...
  69. ncbi Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge
    Joseph J Mattapallil
    Vaccine Research Center, National Institute of Allergy and Infectious Disease (NIAID, National Institutes of Health (NIH, Bethesda, MD 20892, USA
    J Exp Med 203:1533-41. 2006
    ....
  70. ncbi Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2
    Jae Ouk Kim
    Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Bldg 40, MSC 3005, 40 Convent Dr, Bethesda, MD 20892 3005, USA
    J Virol 81:1444-50. 2007
    ..Virions resistant to damage by antibody and complement were sensitive to lysis by sPLA2-X, suggesting a novel mechanism of antiviral surveillance independent of the acquired immune system...
  71. ncbi A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions
    Wei Shi
    Vaccine Research Center, NIAID, National Institutes of Health, Bldg 40, Rm 4502, MSC 3005, 40 Convent Dr, Bethesda, MD 20892 3005, USA
    J Virol 82:6190-9. 2008
    ..The acidic character of this domain is likely responsible for its aberrant biochemical properties. These findings demonstrate that this region is essential for the assembly of the filamentous nucleocapsids that give rise to filoviruses...
  72. ncbi Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies
    Lakshmanan Ganesh
    Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bldg 40, Rm 4502, MSC 3005, 40 Convent Dr, Bethesda, MD 20892 3005, USA
    J Virol 78:11980-7. 2004
    ..This property of DCs may enhance infection, contribute to immune evasion, and could provide a selective advantage for CCR5-tropic virus transmission...
  73. ncbi A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, United States
    Vaccine 29:304-13. 2010
    ..This recombinant Ebola virus vaccine was safe and subjects developed antigen specific humoral and cellular immune responses...
  74. ncbi Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury
    Z Y Yang
    Vaccine Research Center, National Institutes of Health, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nat Med 6:886-9. 2000
    ..These findings indicate that GP, through its mucin domain, is the viral determinant of Ebola pathogenicity and likely contributes to hemorrhage during infection...
  75. ncbi Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination
    Jamal Baig
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 76:11484-90. 2002
    ..These studies therefore suggest that systemic delivery of potent HIV immunogens may suffice to elicit substantial mucosal CTL responses...
  76. ncbi Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys
    Michael S Seaman
    Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, 330 Brookline Ave./RE-113, Boston, MA 02215, USA
    J Virol 79:2956-63. 2005
    ..This study demonstrates that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1...
  77. ncbi Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 172:6290-7. 2004
    ..Moreover, these studies suggest that using Ad vectors derived from immunologically distinct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-existing anti-Ad immunity...
  78. ncbi Medicine. The need for a global HIV vaccine enterprise
    Richard D Klausner
    Bill and Melinda Gates Foundation, Seattle, WA 98102, USA
    Science 300:2036-9. 2003
    ....
  79. ncbi HIV vaccine design and the neutralizing antibody problem
    Dennis R Burton
    Departments of Immunology and Molecular Biology, Scripps Research Institute, La Jolla, California, USA
    Nat Immunol 5:233-6. 2004
  80. ncbi Incorporation of pol into human immunodeficiency virus type 1 Gag virus-like particles occurs independently of the upstream Gag domain in Gag-pol
    Shan Cen
    Lady Davis Institute for Medical Research and McGill AIDS Centre, Jewish General Hospital, McGill University, Montreal, Quebec, Canada H3T 1E2
    J Virol 78:1042-9. 2004
    ....
  81. ncbi Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 77:8729-35. 2003
    ..These data demonstrate that plasmid cytokines can markedly improve the immunogenicity of DNA prime-viral vector boost vaccine strategies and can partially compensate for antivector immunity...
  82. ncbi Adenovirus vector-based vaccines for human immunodeficiency virus type 1
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Hum Gene Ther 16:149-56. 2005
    ..In this review, we describe progress in the development of rAd vector-based vaccines with a focus on human immunodeficiency virus type 1...
  83. ncbi Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys
    Michael S Seaman
    Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, 330 Brookline Ave. RE-113, Boston, MA 02215, USA
    J Virol 79:4580-8. 2005
    ..These data indicate that specific MHC class I alleles can confer protection in the setting of a pathogenic SHIV infection by their ability to elicit memory CTL following vaccination...
  84. ncbi A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Virology 353:268-82. 2006
    ..Our study also shows the feasibility of iterative improvements in Env immunogenicity by rational design of centralized genes...
  85. ncbi Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge
    Yue Sun
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, Boston, MA 02215, USA
    J Virol 80:10950-6. 2006
    ..These findings underscore the contribution of virus-specific central memory T lymphocytes to controlling clinical progression in vaccinated individuals following a primate immunodeficiency virus infection...
  86. ncbi A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys
    Sampa Santra
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:10489-94. 2008
    ..These findings suggest that immunization with centralized genes is a promising vaccine strategy for developing a global vaccine for HIV-1 as well as vaccines for other genetically diverse viruses...
  87. ncbi Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor
    Jae Sung Yu
    Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, United States
    J Virol Methods 137:219-28. 2006
    ..Thus, polyclonal and monoclonal antibodies can be used in combination to identify and differentiate both human and non-human primate EBOV GPs...
  88. ncbi Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen
    Eric A Weaver
    Duke Human Vaccine Institute, Duke University Medical Center, 112 RPIII, Research Drive, Box 3347, DUMC, Durham, NC 27710, USA
    J Virol 80:6745-56. 2006
    ....
  89. ncbi A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 79:8828-34. 2005
    ..This strategy could therefore be explored as a potential method to enhance DNA vaccine immunogenicity in humans...
  90. ncbi Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys
    Paula M Acierno
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115, USA
    J Immunol 176:5338-45. 2006
    ....
  91. ncbi Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells
    Greg M Podsakoff
    Childrens Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA
    Mol Ther 12:77-86. 2005
    ..These findings indicate that there was a selective survival advantage for PBMC containing the huM10 gene during the time of increased HIV-1 load...
  92. ncbi Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates
    Sampa Santra
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P. O. Box 15732, Boston, MA 02215, USA
    J Virol 79:6516-22. 2005
    ..Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection...
  93. ncbi Mapping the future of HIV vaccines
    Gary J Nabel
    Nat Rev Microbiol 5:482-4. 2007
  94. ncbi No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys
    Norman L Letvin
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Virol 81:12368-74. 2007
    ..Rather, innate immune mechanisms or an intact epithelial barrier may be responsible for protection against mucosal infection in this population of monkeys...
  95. ncbi Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes
    Yue Sun
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 174:4753-60. 2005
    ..Persisting clinical protection in vaccinated and challenged monkeys is thus correlated with a preserved capacity of the peripheral blood central memory CD4+ T cells to express this important immunomodulatory cytokine...